Otsuka Pharmaceutical

Total: $62.7 million

Top drug
Abilify: $62.4 million
Watch the TV commercial here >>

Japanese drugmaker Otsuka puts all of its advertising eggs into one product basket, and to good effect. Its atypical antipsychotic Abilify is well-recognized and a blockbuster. The drug is Otsuka's top product and brought in $4.2 billion last year, but it loses exclusivity in 2015. The company recently won FDA approval for a long-acting, once-per-month injectable version of the drug, but it's searching around for products to fill in behind Abilify. The drugmaker may have something new to advertise next year. It recently made an $886 million offer for Astex Pharmaceuticals ($ASTX), which specializes in cancer drugs. The California-based company developed a leukemia drug--Dacogen, marketed by Eisai and Johnson & Johnson's ($JNJ) Janssen unit--but its pipeline is what provides the greatest potential upside.

Otsuka Pharmaceutical
Read more on

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.